본문으로 건너뛰기
← 뒤로

Targeting internalization, resistance, and response: Insights from ICARUS-LUNG01.

2/5 보강
Cancer cell 📖 저널 OA 38.1% 2024: 2/4 OA 2025: 7/18 OA 2026: 15/41 OA 2024~2026 2026 Lung Cancer Treatments and Mutations
Retraction 확인
출처
PubMed DOI OpenAlex 마지막 보강 2026-04-29
OpenAlex 토픽 · Lung Cancer Treatments and Mutations HER2/EGFR in Cancer Research Lung Cancer Research Studies

Sun H, Zhao S, Li J, Zhang L

ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.9%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도

📝 환자 설명용 한 줄

In this issue of Cancer Cell, Planchard et al.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Haishuang Sun, Shen Zhao, et al. (2026). Targeting internalization, resistance, and response: Insights from ICARUS-LUNG01.. Cancer cell. https://doi.org/10.1016/j.ccell.2026.03.001
MLA Haishuang Sun, et al.. "Targeting internalization, resistance, and response: Insights from ICARUS-LUNG01.." Cancer cell, 2026.
PMID 41999748 ↗

Abstract

In this issue of Cancer Cell, Planchard et al. report results from ICARUS-LUNG01, a phase 2 study assessing clinical activity and biomarkers of datopotamab deruxtecan in previously treated non-small cell lung cancer (NSCLC). This study contributes to ongoing efforts to characterize predictors of antibody-drug conjugate efficacy and resistance.

같은 제1저자의 인용 많은 논문 (5)